ARTICLE | Clinical News

Riferminogen pecaplasmid: Phase III final data

December 6, 2010 8:00 AM UTC

Final data from the double-blind, international Phase III TAMARIS trial in 525 patients with CLI and skin lesions who were not eligible for revascularization showed that intramuscular NV1FGF every 2 weeks over a 6-week period led to non-significantly higher rates of major amputation (26% vs. 21%) and death (18% vs. 15%) vs. placebo. Data were presented at the American Heart Association meeting in Chicago. ...